ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD
Overall ASTH gets a fundamental rating of 5 out of 10. We evaluated ASTH against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of ASTH get a neutral evaluation. Nothing too spectacular is happening here. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
In the past year ASTH had a positive cash flow from operations.
Each year in the past 5 years ASTH has been profitable.
In the past 5 years ASTH always reported a positive cash flow from operatings.
1.2 Ratios
ASTH has a Return On Assets of 2.63%. This is in the better half of the industry: ASTH outperforms 61.16% of its industry peers.
ASTH has a better Return On Equity (4.70%) than 60.19% of its industry peers.
ASTH has a Return On Invested Capital (5.19%) which is comparable to the rest of the industry.
ASTH had an Average Return On Invested Capital over the past 3 years of 7.07%. This is below the industry average of 9.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.7% | ||
| ROIC | 5.19% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
ASTH has a Profit Margin (1.56%) which is comparable to the rest of the industry.
ASTH's Profit Margin has declined in the last couple of years.
ASTH's Operating Margin of 3.55% is in line compared to the rest of the industry. ASTH outperforms 55.34% of its industry peers.
ASTH's Operating Margin has declined in the last couple of years.
ASTH has a Gross Margin of 11.94%. This is in the lower half of the industry: ASTH underperforms 72.82% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.55% | ||
| PM (TTM) | 1.56% | ||
| GM | 11.94% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
ASTH has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ASTH is higher compared to a year ago.
2.2 Solvency
ASTH has an Altman-Z score of 3.70. This indicates that ASTH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ASTH (3.70) is better than 70.87% of its industry peers.
The Debt to FCF ratio of ASTH is 8.01, which is on the high side as it means it would take ASTH, 8.01 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 8.01, ASTH perfoms like the industry average, outperforming 56.31% of the companies in the same industry.
ASTH has a Debt/Equity ratio of 0.54. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.54, ASTH perfoms like the industry average, outperforming 58.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 8.01 | ||
| Altman-Z | 3.7 |
ROIC/WACC0.62
WACC8.34%
2.3 Liquidity
A Current Ratio of 1.70 indicates that ASTH should not have too much problems paying its short term obligations.
ASTH has a Current ratio (1.70) which is comparable to the rest of the industry.
A Quick Ratio of 1.70 indicates that ASTH should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.70, ASTH is doing good in the industry, outperforming 62.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.45%.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.81%.
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
Revenue 1Y (TTM)54.81%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
3.2 Future
Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 31.87% on average per year.
The Revenue is expected to grow by 16.61% on average over the next years. This is quite good.
EPS Next Y36.88%
EPS Next 2Y38.32%
EPS Next 3Y39.78%
EPS Next 5Y31.87%
Revenue Next Year42.05%
Revenue Next 2Y32.71%
Revenue Next 3Y27.66%
Revenue Next 5Y16.61%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 34.58, which means the current valuation is very expensive for ASTH.
The rest of the industry has a similar Price/Earnings ratio as ASTH.
Compared to an average S&P500 Price/Earnings ratio of 27.41, ASTH is valued a bit more expensive.
The Price/Forward Earnings ratio is 14.62, which indicates a correct valuation of ASTH.
Based on the Price/Forward Earnings ratio, ASTH is valued a bit cheaper than the industry average as 74.76% of the companies are valued more expensively.
ASTH is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.19, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.58 | ||
| Fwd PE | 14.62 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.86 | ||
| EV/EBITDA | 12.76 |
4.3 Compensation for Growth
ASTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 39.78% in the coming years.
PEG (NY)0.94
PEG (5Y)1.8
EPS Next 2Y38.32%
EPS Next 3Y39.78%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.9
-0.71 (-2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.66%
Inst Owner ChangeN/A
Ins Owners9.71%
Ins Owner Change-10.24%
Market Cap1.24B
Analysts83.53
Price Target51.31 (106.06%)
Short Float %3.77%
Short Ratio5.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP26.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-134.77%
Min EPS beat(2)-225.16%
Max EPS beat(2)-44.39%
EPS beat(4)2
Avg EPS beat(4)-66.81%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)6
Avg EPS beat(8)-18.15%
EPS beat(12)9
Avg EPS beat(12)-1.53%
EPS beat(16)12
Avg EPS beat(16)7.33%
Revenue beat(2)1
Avg Revenue beat(2)1.05%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)8.16%
Revenue beat(8)4
Avg Revenue beat(8)0.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.08%
EPS NQ rev (1m)4.11%
EPS NQ rev (3m)10.5%
EPS NY rev (1m)-2.47%
EPS NY rev (3m)-10.26%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)4.88%
Revenue NY rev (3m)3.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.58 | ||
| Fwd PE | 14.62 | ||
| P/S | 0.55 | ||
| P/FCF | 23.86 | ||
| P/OCF | 19.78 | ||
| P/B | 1.67 | ||
| P/tB | 5.73 | ||
| EV/EBITDA | 12.76 |
EPS(TTM)0.72
EY2.89%
EPS(NY)1.7
Fwd EY6.84%
FCF(TTM)1.04
FCFY4.19%
OCF(TTM)1.26
OCFY5.06%
SpS45.07
BVpS14.93
TBVpS4.35
PEG (NY)0.94
PEG (5Y)1.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.7% | ||
| ROCE | 8.23% | ||
| ROIC | 5.19% | ||
| ROICexc | 7.1% | ||
| ROICexgc | 27.85% | ||
| OM | 3.55% | ||
| PM (TTM) | 1.56% | ||
| GM | 11.94% | ||
| FCFM | 2.32% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 8.01 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 36.16% | ||
| Cap/Sales | 0.48% | ||
| Interest Coverage | 2.55 | ||
| Cash Conversion | 57.41% | ||
| Profit Quality | 148.88% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z | 3.7 |
F-Score5
WACC8.34%
ROIC/WACC0.62
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
EPS Next Y36.88%
EPS Next 2Y38.32%
EPS Next 3Y39.78%
EPS Next 5Y31.87%
Revenue 1Y (TTM)54.81%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
Revenue Next Year42.05%
Revenue Next 2Y32.71%
Revenue Next 3Y27.66%
Revenue Next 5Y16.61%
EBIT growth 1Y-13.63%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year83.9%
EBIT Next 3Y44.03%
EBIT Next 5Y30.85%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A